Clinical trial
A Phase 1, Open-Label Study of LY5830966, a Type II JAK2 Inhibitor, in Patients With Myelofibrosis Previously Treated With a Type I JAK2 Inhibitor, JAK2 Inhibitor-Naïve Myelofibrosis, or High-risk Relapsed/Refractory Polycythemia Vera
NCT06343805 is registered in ClinicalTrials.gov with Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-Label Study of LY5830966, a Type II JAK2 Inhibitor, in Patients With Myelofibrosis Previously Treated With a Type I JAK2 Inhibitor, JAK2 Inhibitor-Naïve Myelofibrosis, or High-risk Relapsed/Refractory Polycythemia Vera
- Lead sponsor
- Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- October 3, 2024
- Completion date
- December 31, 2028
- Enrollment
- 256 (estimated)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.